The purpose of this initiative is to create a registry of subjects with FH across Canada designed to identify subjects with FH and to improve health and healthcare delivery. Rare diseases of lipoprotein metabolism (orphan diseases) will also be included (SMASH registry; Systems and Molecular Approach of Severe Hyperlipidemia). This registry will include clinical, biochemical and demographic information. Specimens (plasma/serum and DNA) will be collected for biobanking. The registry will be made available for clinicians to manage patient care, identify relatives for screening and treatment (cascade screening), to provide advice to general practitioners and to support collaborative studies in biomedical, clinical, health outcomes and health economics research. Access to anonymized data from the registry will be given to researchers, clinicians, biopharmaceutical industry and government by peer-reviewed process.